Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion announced a $200 million oversubscribed follow-on offering with leading healthcare investors including Janus Henderson, ARK Invest, and Invus, alongside pipeline and partnership updates. REC-4881 showed a 47% median total GI polyp burden reduction in FAP after 12 weeks with durability off treatment, and a registrational trial is targeted for 2H 2027 pending FDA discussions; REC-1245 posted 2 confirmed partial responses and a 91.7% disease control rate in Phase 1.
Key figures
- Deal Value Usd
- 200000000
- Cash runway
- into 2029
- Cash position
- $561 million (Sept 30, 2026, preliminary/unaudited)
- Sanofi milestone
- $10 million option milestone
- Sanofi total payments
- $144 million to date
- Fap market opportunity
- $15 billion (company estimate)
- Sanofi remaining milestones
- more than $300 million
- Rec 1245 disease control rate
- 91.7% (11/12) at doses ≥45 mg
- Rec 4881 median polyp reduction total gi
- 47% after 12 weeks
- Rec 4881 median polyp reduction upper gi
- 55%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.